Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in
signal transduction initiated by a wide range of membrane receptors. Among the proteins in …

Although the rates of many cancers are controlled in Western countries, those of some
cancers, such as lung, breast, and colorectal cancer are currently increasing in many low …

Prosenescence therapy has recently emerged as a novel therapeutic approach for treating
cancer. However, this concept is challenged by conflicting evidence showing that the …

Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …

We investigated the therapeutic potential of JQ1, an inhibitor of the BET class of human
bromodomain proteins, in B-cell acute lymphoblastic leukemia (B-ALL). We show that JQ1 …

In the past decades, studies of the Janus kinases (JAKs) and signal transducers and
activators of transcription (STATs) signaling have uncovered highly conserved programs …

Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in
cancer patients, but clinical responses are limited. Cytokine signaling through the Janus …

JAK inhibitors have been developed following the discovery of the JAK2V617F in 2005 as
the driver mutation of the majority of non-BCR-ABL1 myeloproliferative neoplasms (MPNs) …

Summary Hyperactive PI3K/mTOR signaling is prevalent in human malignancies and its
inhibition has potent antitumor consequences. Unfortunately, single-agent targeted cancer …

Recent advances in our understanding of the pathogenesis of the Philadelphia chromosome-
negative myeloproliferative neoplasms, polycythaemia vera, essential thrombocythaemia …